Skip to content

Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section

Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section. Controlled Comparative Study.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02279628
Enrollment
150
Registered
2014-10-31
Start date
2014-07-31
Completion date
2017-06-30
Last updated
2014-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Keywords

cesarean section, spinal anesthesia, continuous wound infiltration, intrathecal morphine, oral morphine

Brief summary

The cesarean section is considered as a painful surgery during the post operative period. Mothers may need to move immediately after the surgery to take care of their babies. This may increase the risk of major pain and chronic pain. Thus, excellent postoperative analgesia is required so that mothers do not experience pain in caring for their baby. Currently, several techniques have been developed to manage postoperative pain related to c-section scar such as intrathecal morphine during spinal anesthesia or continuous pre-peritoneal wound infiltration. The comparison between anesthetic techniques has never been performed and it is still not know if the combination of intrathecal morphine plus continuous pre-peritoneal wound infiltration provide a synergistic or additional effect on pain relief.

Detailed description

The aim of this study is to compare the efficacy of continuous wound infiltration versus intrathecal morphine for postoperative analgesia after scheduled cesarean section. The primary endpoint is morphine consumption during the first 48 postoperative hours.

Interventions

DRUGRopivacaine

Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)

DRUGMorphine

Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period

Sponsors

Maternite Regionale Universitaire
CollaboratorOTHER
Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Elective Cesarean section * Spinal anesthesia * Singleton * ASA ( Physical status score) 1 to 3

Exclusion criteria

* Age \<18yrs * BMI ≥ 45 kg/m2 or weight \< 45 kg * Refusal to consent * Urgent cesarean section * Allergy to a medication used in the protocol * Impaired hemostasis ou current infection * Contra indication or failure of spinal anesthesia

Design outcomes

Primary

MeasureTime frame
Morphine consumption during the first 48 postoperative hoursat the 48th hour

Secondary

MeasureTime frameDescription
Time to restoration of bowel functionwithin the first 48 postoperative hours
Verbal and Visual analog pain scores in the first standing positionat day 1
Number of patients that required oral morphineAt the 24th and 48th hour
Pain at rest and at mobilizationEvery 4 hours during the first 48 postoperative hoursThe pain at rest and at mobilization will be evaluated with both Visual Analog scale and Verbal pain scale. The patient should describe the worst pain felt during the previous 4 hours in a lying position and at mobilization
Postoperative rehabilitation surveyAt the 48th hour
Occurrence of side effectDuring the first 48 hoursItching, nausea and vomiting, drowsiness, urinary retention, hypoventilation, other will be assessed with a questionnaire
Postoperative residual pain (DN4 survey)At 3 months postoperatively
Number of patients that required local anesthetic rescue dose through the catheterAt the 24th and 48th hour

Countries

France

Contacts

Primary ContactFlorence VIAL, MD
f.vial@maternite.chu-nancy.fr+ 33 3 83 34 43 67
Backup ContactPhilippe GUERCI, MD
p.guerci@chu-nancy.fr+33 3 83 15 73 99

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026